Heartbeam Inc (BEAT)

Nov 2, 2026

This article details how four stocks—Once Upon a Farm (NYSE:OFRM), Precigen (NASDAQ:PGEN), PMGC Holdings (NASDAQ:ELAB), and HeartBeam (NASDAQ:BEAT)—experienced significant declines of up to 27% due to specific company-related events. Once Upon a Farm fell following a product recall, Precigen dropped after a rival treatment received FDA approval, PMGC Holdings saw its stock decline despite a SPAC deal announcement, and HeartBeam decreased after presenting heart attack study data at a conference. The report examines the individual circumstances behind each stock's downturn, providing financial details and market reactions.

Nov 2, 2026

HeartBeam (NASDAQ: BEAT) announced positive results from its ALIGN-ACS pilot study, demonstrating that its patient-recorded 3D ECG system is as accurate as a standard 12-lead ECG for heart attack assessment. The study, presented at TCT 2026, showed higher specificity and comparable sensitivity for the HeartBeam device, with 100% patient success in self-recording. These findings support the potential for remote heart attack assessment and will inform a U.S. pivotal study in Q1 2027.

Nov 2, 2026

HeartBeam, Inc. announced results from a 132-patient pilot study comparing its portable ECG system with standard 12-lead ECGs for acute coronary syndrome assessment. The study showed HeartBeam's device achieved higher specificity (81.8% vs. 71.4%) but slightly lower sensitivity (60.2% vs. 63.0%). The company plans a U.S. pivotal trial in Q1 2027 to further investigate its heart attack assessment technology, which has FDA Breakthrough Device Designation.